Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
Launched by DENDREON · May 28, 2010
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Histologically documented adenocarcinoma of the prostate
- • Metastatic disease as evidenced by soft tissue and/or bony metastases
- • Prostate-specific antigen value of at least 5 ng/mL
- • Tumor progression while on hormonal therapy
- • Castration levels of testosterone (defined as less than 50 ng/dL)
- • Life expectancy of at least 16 weeks
- • Adequate hematologic, renal, and liver function
- Exclusion Criteria:
- • Visceral organ metastases
- • Metastatic disease expected to be in need of radiation therapy within 4 months.
- • Concurrent therapy with experimental agents
About Dendreon
Dendreon is a leading biotechnology company focused on advancing innovative immunotherapy treatments for cancer. With a commitment to harnessing the body's immune system to target and fight cancer cells, Dendreon is dedicated to developing groundbreaking therapies that improve patient outcomes and quality of life. The company is known for its pioneering work in the field of cancer immunotherapy, particularly its FDA-approved treatment, Provenge, for prostate cancer. By prioritizing research and clinical trials, Dendreon aims to expand its portfolio of cancer therapies and contribute significantly to the evolving landscape of oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials